Episode Details

Back to Episodes
Pharmaceutical Executive Daily: Eli Lilly Enters $2.8 Billion Agreement to Acquire Merida Biosciences

Pharmaceutical Executive Daily: Eli Lilly Enters $2.8 Billion Agreement to Acquire Merida Biosciences

Published 2 months, 2 weeks ago
Description
Eli Lilly agrees to acquire Merida Biosciences for up to $2.875 billion, BioNTech halts a Phase II trial of its cancer immunotherapy Cevumeran, and Parth Khanna argues that more competitive data doesn't mean better intelligence in pharma.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us